• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Pear Therapeutics to develop digital therapeutic for sleep/wake disorder in Japan

March 21, 2022 By Sean Whooley

Pear TherapeuticsPear Therapeutics (Nasdaq:PEAR) announced today that it entered an agreement to develop a Japanese-language digital therapeutic.

Boston-based Pear struck a deal with SoftBank, a Japan-based communication and information technology service provider, to develop the digital therapeutic for the treatment of sleep/wake disorders on the Japanese market.

Pear Therapeutics markets the Somryst prescription digital therapeutic (PDT) in the U.S. The company designed Somryst to address the underlying issues of chronic insomnia by delivering cognitive behavioral therapy for insomnia (CBTi), training the body to sleep.

The nine-week PDT can be used on a mobile device as the only FDA-authorized therapeutic that delivers guideline-recommended first-line treatment for chronic insomnia. Last week, the company shared data from two studies that highlight Somryst’s effectiveness.

Pear’s strategic partnership with SoftBank will see the company develop digital therapeutic applications for treating sleep/wake disorders in Japan, with SoftBank set to investigate the Japanese market potential for such applications. SoftBank also has an option to negotiate an exclusive license for Pear’s digital therapeutics for sleep/wake disorders in Japan.

“Our agreement with SoftBank supports our mission to bring digital treatment options to patients outside of the United States. The Japanese market has a large unmet need in treating people with sleep disorders,” Pear President and CEO Dr. Corey McCann said in a news release. “This opportunity fits squarely in our strategy to bring our PDTs to patients around the globe.”

BTIG analyst Marie Thibault said in a report that, while it remains unclear over whether a Japan-specific digital therapeutic would require regulatory approval, there is encouragement from the fact that Pear has taken steps to expand its presence in international markets.

Filed Under: Business/Financial News, Featured, Neurological, Technology Tagged With: Pear Therapeutics

IN CASE YOU MISSED IT

  • Abbott could pave new roads in diabetes management with dual sensor on the horizon
  • Tandem Diabetes Care pairs t:slim X2 pump with Abbott FreeStyle Libre 3 Plus in U.S.
  • Ypsomed, CamDiab to integrate Abbott dual glucose-ketone sensor into automated insulin delivery system
  • PharmaSens, SiBionics collab on all-in-one insulin patch pump
  • Beta Bionics to pair iLet automated insulin delivery system with Abbott’s dual glucose-ketone sensor

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at swhooley@wtwhmedia.com.

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS